In CLL, scRNA-seq has helped to resolve the transcriptomic changes and alternative splicing effects of SF3B1 mutations, a common subclonal event associated with clinically aggressive disease (Figure 4) (41). The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.